Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
about
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in miceChapter 7: PharmacogenomicsPossible interaction between warfarin and cranberry juiceCytochrome P4502C9: an enzyme of major importance in human drug metabolismClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonWarfarin pharmacogenetics: does more accurate dosing benefit patients?Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinGliclazide hydroxylation by rat liver microsomesClinical relevance of genetic polymorphisms in the human CYP2C subfamilyWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsWarfarin Pharmacogenetics: New Life for an Old DrugDistal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarinComparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort StudyGenetic factors associated with patient-specific warfarin dose in ethnic Indonesians10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarinAssessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.Pharmacogenetics of warfarin: challenges and opportunities.Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver.Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum.CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.The importance of drug interactions in epilepsy therapy.Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Pharmacogenetics of anticoagulants.Warfarin dosing in patients with impaired kidney functionWarfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.Inhibition of human cytochromes P450 by components of Ginkgo biloba.High clearance of (S)-warfarin in a warfarin-resistant subjectCommon VKORC1 and GGCX polymorphisms associated with warfarin dose.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Liver enzyme induction and inhibition: implications for anaesthesia.Genetics of warfarin sensitivity in an emergency department population with thromboembolic.Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.Association of warfarin dose with genes involved in its action and metabolism.Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.
P2860
Q21090145-61035101-74B4-492B-8B75-0DC85A7A9019Q21563496-6392739F-D433-4CB5-B9E3-B2FA83EFCD76Q24623457-8C1079C5-9E6E-418F-B3E2-D43C1F595E8CQ24683497-84B2195B-ABAE-4A85-BA04-627410D07792Q26823542-326FBBC1-EE8E-4DB6-8FB1-972B34BD1E0EQ27006860-0A882A8F-B119-4DB2-B1C6-9988E064293CQ27027304-390A8CB2-2CF5-4901-ABCC-D0060FFD3CC4Q28083875-85FBF7A2-48F2-4B10-B6E5-E1EADEE4D186Q28276514-EDC828EE-076A-4962-903D-E40BAE7BDCF9Q28285280-17DA8FF9-310A-4E77-9F7E-DAC98B1A6779Q28362533-E520FDAD-CB9D-4014-B709-F7F5831B37D5Q28395337-2084ACB7-DEC8-453D-B739-FEAFBB7756B9Q28468726-72601F90-BEAC-48A0-ACC7-620166CF86A0Q28536483-EBDC4DFC-C8A3-4396-8AEF-778B0F504866Q28552407-4988C294-F04B-4B7F-A2A3-89240EA97950Q31016306-89E9C0C8-1D8F-4620-B35B-09D5FA94860DQ33517162-B67DD943-8C31-4A41-81FE-0F35BAC12C29Q33606800-1A5D06A6-3256-4F42-AB5F-8A5A05505D48Q33614759-A133BA82-89F2-4270-A592-ADE1441BE829Q33644101-E41076BF-D000-4583-8363-2C23D573B962Q33819050-C4D96F22-9CD1-4679-A78D-22CB6B6B84CEQ33901952-58F311C7-ADF1-40B9-A0F7-2C8A8D7C7609Q33912911-40A7FA14-8615-482A-8396-6FA4BA76FE21Q33990359-F7F30827-2B9D-4D39-8424-11D9052F34ACQ34026245-C50B7E7E-E6C3-4381-8DB5-2125894AF086Q34103300-FFF2CBCE-C7C6-4EA8-9E39-659F362CC511Q34123652-092C1A1C-E54D-4C76-9D98-F1AFDDA15D5AQ34188511-72D54522-50C3-4CC5-98DB-BBAAAB5609E6Q34219746-D44783A4-F1A8-4352-81ED-AC0C31E67C54Q34238435-D8191BAE-6288-4179-A5DE-709F0DF62735Q34283903-8A445EC6-D8D4-4746-BF72-7178EE2BF70BQ34337497-3B1A57FC-9F91-41EA-8F71-40E4BF966291Q34403760-2ECB9E99-163C-4A7A-8CFD-206D334A85E1Q34417386-D444230D-8704-468A-980E-9D3962EA2BA5Q34418092-2492DFAA-B54E-421C-B255-B6E14C86E849Q34487131-4AAC317E-53A2-41A1-86E2-780ECFB71683Q34934523-B49E8A79-9A0B-455C-BF1A-C3E390C48561Q35204081-DBF4302B-4A3E-4EF2-A63A-F79314371703Q35633802-E9AEC305-7913-47A4-B685-76FD0388DE9BQ35656097-D2C6E236-E4E7-4933-97FB-7AF49A12CBDF
P2860
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Hydroxylation of warfarin by h ...... S)-warfarin-drug interactions.
@en
Hydroxylation of warfarin by h ...... or P-4502C9 in the etiology of
@nl
type
label
Hydroxylation of warfarin by h ...... S)-warfarin-drug interactions.
@en
Hydroxylation of warfarin by h ...... or P-4502C9 in the etiology of
@nl
prefLabel
Hydroxylation of warfarin by h ...... S)-warfarin-drug interactions.
@en
Hydroxylation of warfarin by h ...... or P-4502C9 in the etiology of
@nl
P2093
P356
P1476
Hydroxylation of warfarin by h ...... S)-warfarin-drug interactions.
@en
P2093
Gelboin HV
Gonzalez FJ
Korzekwa KR
Lawrence RF
P356
10.1021/TX00025A009
P577
1992-01-01T00:00:00Z